SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NPSP NPS Pharmaceutical
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
363 40 0 NPSP
Emcee:  Jim Langdon Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
263This one looks punished enough. They seem to have a solid pipeline with Preos rLJM-4/13/2005
262New TOP Study Data Analyses of PREOS Show Improved Bone Microarchitecture and Remopgcw-4/7/2005
261SSB: OPINION We provide a summary of key takeaways from our Smith Barney Healthmopgcw-4/5/2005
260Some decent insider buys: 11-Mar-05 KLEIN, JOSEPH III Director 10,000 Purchase mopgcw-3/20/2005
259>>NPS Pharma sinks on analysts' views By Val Brickates Kennedy, Marketuck-3/9/2005
258SSB: BUY (1) Speculative (S) Mkt Cap: $594 mil. February 7, 2005 mopgcw-2/15/2005
257Some PREOS delays but don't appear to be major... NPS Provides Update on PRFiloF-2/8/2005
256SSB: NPS Pharmaceuticals (NPSP, Buy, Speculative) Reporting date: Tuesday, Marmopgcw-1/27/2005
255GS: NPSP(IL/N): Financing adds capital without dilution. Reduces Sensipar upsidemopgcw-1/6/2005
254>>SALT LAKE CITY, Nov. 30 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-11/30/2004
253I think NPSP will have a hard time marketing PREOS because of the mode of adminiSpekulatius-11/16/2004
252LEIN III JOSEPH,Director,BUYS 10,000 ON 11/10/04 OF NPSP 2004-11-12 11:26 (New Ymopgcw-11/15/2004
251Revenues a just slightly light, but earnings better than estimates. Sensipar aptuck-11/8/2004
250Sensipar approved in Europe: Message 20697055 Cheers, Tucktuck-10/28/2004
249SSB: NPSP: Believe Stock Weakness an Overreaction to Safety Concerns with Preos mopgcw-10/26/2004
248GS: NPSP (IL/N): Analyst mtg. highlights data and launch plans for Preos 52-Weemopgcw-10/25/2004
247GS: NPSP (IL/N): Preos effective in early and late osteoporosis, but more side fmopgcw-10/25/2004
246GS: NPS Pharmaceuticals, Inc. EPS (FY Dec) 2004E ($4.09), 2005E ($3.50) In-Line/mopgcw-10/25/2004
2450.7% for serum and 2.4% for urine (more important) isn't trivial, imo. SecoMiljenko Zuanic-10/21/2004
244>>SALT LAKE CITY, Oct. 21 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-10/21/2004
243Point taken. >>SALT LAKE CITY, Oct. 19 /PRNewswire-FirstCall/ -- NPS Phartuck-10/19/2004
242>>Fairly minor setback unless it is indicative of failure in other indicatIcebrg-10/12/2004
241[NPS 1776 (isovaleramide) in patients with moderate to severe migraine headachestuck-10/12/2004
240>>SALT LAKE CITY, Oct. 4 /PRNewswire/ -- As the paradigm for the treatmenttuck-10/4/2004
239Folks on Yahoo board attempting to read the Sensipar scrips data seem to think ituck-8/9/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News